Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUAN C GARZA

Allopathic & Osteopathic Physicians Family Medicine

NPI
1669449971
CMS profile
165973
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,566.78

94 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,566.78 94

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 94 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUAN C GARZA

NPI 1669449971 · CMS profile ID 165973

Allopathic & Osteopathic Physicians / Family Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 94 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669449971?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUAN C GARZA, NPI 1669449971, CMS profile ID 165973. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 94 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669449971?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JUAN C GARZA, NPI 1669449971, CMS profile ID 165973. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 94 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669449971?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JUAN C GARZA, NPI 1669449971, CMS profile ID 165973, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 94 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1669449971?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

94 matching records · $1,566.78 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 94 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 94.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.5612/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057254523 CMS
ABBVIE INC. $13.2712/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997322603 CMS
Novo Nordisk Inc $22.2712/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001022091 CMS
Shield Therapeutics Inc $15.3512/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045855561 CMS
Regeneron Healthcare Solutions, Inc. $23.5311/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999182197 CMS
Novo Nordisk Inc $10.9911/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001021965 CMS
ABBVIE INC. $24.7511/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997322601 CMS
Bayer Healthcare Pharmaceuticals Inc. $14.6511/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000072483 CMS
PFIZER INC. $4.4311/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050522439 CMS
ABBVIE INC. $11.8411/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997322599 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.0311/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057194961 CMS
Lilly USA, LLC $15.5311/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031646979 CMS
ABBVIE INC. $21.6811/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997322597 CMS
ABBVIE INC. $16.7010/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997322595 CMS
Kowa Pharmaceuticals America, Inc. $16.9010/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003760565 CMS
ABBVIE INC. $19.3810/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997322593 CMS
ABBVIE INC. $11.0110/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997322591 CMS
Novo Nordisk Inc $16.7710/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001022011 CMS
PFIZER INC. $2.0910/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050426909 CMS
PFIZER INC. $16.5310/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049332533 CMS
Lilly USA, LLC $20.7509/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031867565 CMS
ABBVIE INC. $13.4609/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997322589 CMS
ABBVIE INC. $18.7409/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997322587 CMS
GlaxoSmithKline, LLC. $13.5209/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002742199 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.3709/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057434287 CMS
Novo Nordisk Inc $19.8709/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001022054 CMS
AstraZeneca Pharmaceuticals LP $17.3909/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011957487 CMS
ABBVIE INC. $20.0609/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997322585 CMS
PFIZER INC. $22.5609/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050576227 CMS
Bayer Healthcare Pharmaceuticals Inc. $10.1909/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000044361 CMS
AstraZeneca Pharmaceuticals LP $12.7409/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014971885 CMS
PFIZER INC. $11.3309/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050697983 CMS
Ironwood Pharmaceuticals, Inc $27.2209/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045541103 CMS
Teva Pharmaceuticals USA, Inc. $25.6208/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056855223 CMS
Lilly USA, LLC $9.9908/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031867569 CMS
ABBVIE INC. $23.6808/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997322583 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.7408/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000110929 CMS
Lilly USA, LLC $19.8908/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031611633 CMS
Novo Nordisk Inc $14.8308/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001021975 CMS
ABBVIE INC. $8.6508/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997322581 CMS
Novo Nordisk Inc $1.0508/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001021953 CMS
ABBVIE INC. $18.7707/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997322579 CMS
ABBVIE INC. $7.9807/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997322577 CMS
Lilly USA, LLC $1.0407/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031611635 CMS
Lilly USA, LLC $10.2407/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031867575 CMS
Novo Nordisk Inc $22.0007/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001022075 CMS
Lilly USA, LLC $7.9907/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031739233 CMS
Lilly USA, LLC $2.5107/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031845209 CMS
Novo Nordisk Inc $16.0907/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001021987 CMS
Novo Nordisk Inc $113.4207/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001022111 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $697.42 45
PY2020 $462.87 34
PY2021 $606.41 45
PY2022 $1,514.63 68
PY2023 $1,566.78 94
PY2024 $1,681.91 93
PY2025 $1,387.30 78

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $43,373.43 14
PY2024 Principal investigator $171,802.76 70
PY2023 Recipient $23,812.92 7
PY2023 Principal investigator $383,116.06 124
PY2022 Principal investigator $624,521.08 179
PY2021 Principal investigator $663,885.83 360
PY2020 Principal investigator $248,213.43 166
PY2019 Principal investigator $403,386.63 210

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

131 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $9,930.01 12/31/2023 Non-covered Recipient Entity
VIP Trials
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1042522825
Principal investigator 1 Merck Sharp & Dohme LLC $125,114.20 12/31/2023 Non-covered Recipient Entity
VIP Trials
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults No dispute reported 06/30/2026 1042567481
Principal investigator 1 Novo Nordisk AS $1,279.80 12/18/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1006790011
Principal investigator 1 Novo Nordisk AS $2,702.83 12/18/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007017355
Principal investigator 1 Biogen, Inc. $2,516.55 12/14/2023 Non-covered Recipient Entity
Vip Trials
A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS) No dispute reported 06/30/2026 1012184063
Principal investigator 1 Novo Nordisk AS $871.87 11/27/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007017337
Principal investigator 1 Novo Nordisk AS $1,585.99 11/27/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1007276859
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,171.00 11/22/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041961
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,521.00 11/22/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041967
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,171.00 11/22/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997042009
Principal investigator 1 Merck Sharp & Dohme LLC $65,331.48 11/20/2023 Non-covered Recipient Entity
VIP Trials
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults No dispute reported 06/30/2026 1042567471
Recipient PFIZER INC. $2,034.69 10/26/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046052510
Principal investigator 1 Novo Nordisk AS $600.00 10/25/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
EX9536-4388 No dispute reported 06/30/2026 1008223635
Principal investigator 1 Novo Nordisk AS $3,598.58 10/23/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1006789997
Principal investigator 1 Novo Nordisk AS $2,356.87 10/23/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007017323
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,171.00 10/18/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,481.00 10/18/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041955
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,144.10 10/06/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,683.00 10/06/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,171.00 10/06/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041973
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,171.00 10/06/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041979
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,171.00 10/06/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,171.00 10/06/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041991
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,171.00 10/06/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041997
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,171.00 10/06/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997042003
Principal investigator 1 Novo Nordisk AS $57.40 10/05/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1006789961
Principal investigator 1 Novo Nordisk AS $8.91 10/05/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1006789973
Principal investigator 1 Novo Nordisk AS $90.00 10/05/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1006789985
Principal investigator 1 Novo Nordisk AS $88.92 10/05/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1008980279
Principal investigator 1 Novo Nordisk AS $5.20 10/05/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1008980295
Principal investigator 1 Novo Nordisk AS $23.64 10/05/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1008980307
Principal investigator 1 Novo Nordisk AS $1,573.87 09/22/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007017291
Principal investigator 1 Novo Nordisk AS $5,311.14 09/22/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1007836623
Principal investigator 1 Novo Nordisk AS $1,458.35 09/22/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
EX9536-4388 No dispute reported 06/30/2026 1008223621
Principal investigator 1 Novo Nordisk AS $3.94 09/21/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1008980249
Principal investigator 1 Novo Nordisk AS $23.06 09/21/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1008980263
Recipient PFIZER INC. $890.55 09/14/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046151295
Principal investigator 1 Novo Nordisk AS $426.60 08/18/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1007276847
Principal investigator 1 Novo Nordisk AS $4,767.86 08/18/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
EX9536-4388 No dispute reported 06/30/2026 1008223607
Principal investigator 1 Novo Nordisk AS $23.06 08/09/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007017305
Principal investigator 1 Novo Nordisk AS $3.94 08/04/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1007836629
Principal investigator 1 Novo Nordisk AS $23.06 08/04/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1007836636
Recipient PFIZER INC. $1,568.14 08/03/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046307915
Principal investigator 1 Novo Nordisk AS $23.06 08/02/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1008391465
Principal investigator 1 Novo Nordisk AS $3.94 08/01/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1008980221
Principal investigator 1 Novo Nordisk AS $23.06 08/01/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1008980237
Principal investigator 1 Novo Nordisk AS $1,723.50 07/31/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007017275
Principal investigator 1 Novo Nordisk AS $1,706.40 07/31/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1007836617
Principal investigator 1 Novo Nordisk AS $2,475.00 07/31/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
EX9536-4388 No dispute reported 06/30/2026 1008223589
Principal investigator 1 Novo Nordisk AS $1,141.79 07/26/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
EX9536-4388 No dispute reported 06/30/2026 1008223557
Principal investigator 1 Novo Nordisk AS $500.00 07/26/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
EX9536-4388 No dispute reported 06/30/2026 1008223575
Principal investigator 1 Novo Nordisk AS $2.97 07/25/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1006775919
Principal investigator 1 Novo Nordisk AS $23.06 07/25/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1007836611
Principal investigator 1 Novo Nordisk AS $23.06 07/18/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007017243
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 07/17/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,562.00 07/17/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,125.00 07/17/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,500.00 07/17/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041891
Principal investigator 1 PFIZER INC. $2,537.89 07/13/2023 Non-covered Recipient Entity
VIP TRIALS LLC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046032771
Principal investigator 1 Novo Nordisk AS $87.32 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007017227
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007766393
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007766399
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007766405
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007766413
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007766419
Principal investigator 1 Novo Nordisk AS $15.98 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1008391479
Principal investigator 1 Novo Nordisk AS $14.98 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1008391497
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1008391511
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1008391525
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1008391539
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1008391555
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1008391569
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1008391583
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1008391599
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1008391614
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1008391629
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1008391643
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1008391657
Principal investigator 1 Novo Nordisk AS $19.98 06/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1008391671
Principal investigator 1 Novo Nordisk AS $373.50 06/23/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007017257
Principal investigator 1 Novo Nordisk AS $6,290.91 06/23/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1007276837
Principal investigator 1 Novo Nordisk AS $8,944.28 06/23/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
EX9536-4388 No dispute reported 06/30/2026 1008223543
Principal investigator 1 PFIZER INC. $1,695.71 06/22/2023 Non-covered Recipient Entity
VIP TRIALS LLC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1045898907
Principal investigator 1 Eli Lilly and Company $1,034.79 06/14/2023 Non-covered Recipient Entity
VIP TRIALS LLC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1038149493
Recipient Eli Lilly and Company $1,083.36 06/11/2023 Covered Recipient Physician A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1038063323
Principal investigator 1 PFIZER INC. $6,250.00 06/03/2023 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046025129
Principal investigator 1 Novo Nordisk AS $4,151.75 06/02/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1007276827
Recipient PFIZER INC. $1,780.76 05/25/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046346411
Recipient PFIZER INC. $15,715.41 05/25/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046347047
Principal investigator 1 Novo Nordisk AS $20.10 05/12/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
EX9536-4388 No dispute reported 06/30/2026 1008223527
Principal investigator 1 ABBVIE INC. $3,300.00 04/20/2023 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998379065
Recipient Eli Lilly and Company $740.01 04/10/2023 Covered Recipient Physician A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1038063317
Principal investigator 1 Eli Lilly and Company $363.68 03/24/2023 Non-covered Recipient Entity
ADVANCED CLINICAL RESEARCH INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1038066105
Principal investigator 1 Eli Lilly and Company $916.30 03/24/2023 Non-covered Recipient Entity
VIP TRIALS LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1038156477
Principal investigator 1 Novo Nordisk AS $1,915.44 03/24/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
EX9536-4388 No dispute reported 06/30/2026 1006819793
Principal investigator 1 Novo Nordisk AS $4,278.32 03/24/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1007276815
Principal investigator 1 Novo Nordisk AS $823.50 03/24/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007400379
Principal investigator 1 Novo Nordisk AS $23.06 03/02/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1006775893
Principal investigator 1 Novo Nordisk AS $8.20 03/02/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1006775907
Principal investigator 1 PFIZER INC. $3,960.00 02/28/2023 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046295657
Principal investigator 1 ABBVIE INC. $3,110.40 02/22/2023 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998371601
Principal investigator 1 Novo Nordisk AS $500.00 02/22/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1006775881
Principal investigator 1 Novo Nordisk AS $7,735.41 02/22/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
EX9536-4388 No dispute reported 06/30/2026 1006819781
Principal investigator 1 Novo Nordisk AS $1,000.00 02/22/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007400369
Principal investigator 1 Novo Nordisk AS $2,012.59 02/22/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1009702459
Principal investigator 1 Novo Nordisk AS $8.20 01/31/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1006775843
Principal investigator 1 Novo Nordisk AS $23.06 01/31/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1006775855
Principal investigator 1 Novo Nordisk AS $19.98 01/30/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007400349
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,800.00 01/26/2023 Non-covered Recipient Entity
VIP TRIALS LLC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046007835
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $200.00 01/26/2023 Non-covered Recipient Entity
VIP TRIALS LLC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046012847
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $12,130.01 01/26/2023 Non-covered Recipient Entity
VIP TRIALS LLC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046127265
Principal investigator 1 Novo Nordisk AS $1,706.40 01/25/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1006775869
Principal investigator 1 Novo Nordisk AS $1,223.72 01/25/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
EX9536-4388 No dispute reported 06/30/2026 1006819769
Principal investigator 1 Novo Nordisk AS $747.00 01/25/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007400393
Principal investigator 1 Novo Nordisk AS $23.06 01/24/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1006775819
Principal investigator 1 Novo Nordisk AS $23.06 01/24/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1006775831
Principal investigator 1 Novo Nordisk AS $2.75 01/24/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1007931821
Principal investigator 1 Novo Nordisk AS $2.97 01/24/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1007931831
Principal investigator 1 Novo Nordisk AS $11.64 01/23/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
EX9536-4388 No dispute reported 06/30/2026 1006819757
Principal investigator 1 Alnylam Pharmaceuticals Inc. $21.00 01/20/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041649
Principal investigator 1 Alnylam Pharmaceuticals Inc. $100.00 01/20/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041655
Principal investigator 1 Alnylam Pharmaceuticals Inc. $816.00 01/20/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041663
Principal investigator 1 Alnylam Pharmaceuticals Inc. $760.00 01/20/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041669
Principal investigator 1 Alnylam Pharmaceuticals Inc. $104.00 01/20/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041675
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,699.00 01/20/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $228.00 01/20/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041687
Principal investigator 1 Alnylam Pharmaceuticals Inc. $375.00 01/20/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041693
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,030.20 01/20/2023 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041699
Principal investigator 1 Novo Nordisk AS $23.06 01/17/2023 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1007400359
Principal investigator 1 ABBVIE INC. $445.50 01/12/2023 Non-covered Recipient Entity
VIP TRIALS
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998366529
Principal investigator 1 Eli Lilly and Company $557.17 01/10/2023 Non-covered Recipient Entity
VIP TRIALS LLC
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1038149487